NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jan 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
EVEKEO ODT (amphetamine sulfate) by R-Pharm US is non-catecholamine sympathomimetic amines with cns stimulant activity. Approved for attention deficit hyperactivity disorder. First approved in 2019.
Drug data last refreshed 20h ago
Mechanism of Action
non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD is not known.
Indications (1)
Company
Worked on EVEKEO ODT at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.